Advertisement


Tycel J. Phillips, MD, and Alex F. Herrera, MD, on DLBCL: New Data on ctDNA Status and Clinical Outcomes

2023 ASCO Annual Meeting

Advertisement

Tycel J. Phillips, MD, and Alex F. Herrera, MD, both of the City of Hope National Medical Center, discuss findings from the POLARIX study, which provided the largest prospectively collected circulating tumor DNA (ctDNA) data set on patients with previously untreated diffuse large B-cell lymphoma. Achieving ctDNA-negative status was associated with improved outcomes when patients were treated with polatuzumab vedotin-piiq plus combination chemotherapy vs combination chemotherapy alone (Abstract 7523).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Tycel J. Phillips: Dr. Herrera, thank you for being here. Talk us through the subset analysis of the POLARIX study. Alex F. Herrera: Absolutely. So, POLARIX, as you know, was a randomized, phase 3 trial in previously untreated diffuse large B-cell lymphoma patients, comparing the old standard R-CHOP to polatuzumab vedotin combined with R-CHP, so dropping vincristine. Now, a really exciting part of the study is that we collected blood both at baseline and at different time points to assess circulating tumor DNA, this exciting biomarker that we have, to try to understand the depth of response in real time on studies. Tycel J. Phillips: Sure. Alex F. Herrera: So, this particular analysis was looking at patients who had paired samples that were assessed for ctDNA, looking at pair-based samples from baseline and cycle five day one or baseline and end of treatment. Tycel J. Phillips: Okay. Alex F. Herrera: So, what we found is that when you looked at both cycle five day one and end of treatment, patients who had cleared their ctDNA had better outcomes than patients who did not, if you pooled the two arms together. That was kind of the most significant finding, really validating this concept that circulating tumor DNA can be used as a prognostic marker, and potentially maybe someday to guide therapy or to at least design clinical trials where we can test that. The other interesting thing that we found was if you looked at patients in a complete response on a PET scan and then you looked at patients who had their clear ctDNA, actually the patients in the pola-R-CHP arm actually did a little better than the patients in the R-CHP arm. So, maybe that suggests that patients who received pola-R-CHP had deeper responses. I suppose the other side of that though is that the assay couldn't identify those deeper responses. Tycel J. Phillips: I mean, so with this information, and we could both be very transparent, it's been a very sort of controversial positive study, which just seems to be the trend lately. Alex F. Herrera: Yeah. Tycel J. Phillips: Sort of, I guess what information can we take forward as we sort of look at this? Is it this we just need a better assay to predict who's a better patient, who may get more responsible pola-R-CHP? Or is there something else we should be doing differently? Alex F. Herrera: That's a great question. I think based on these data we have, in a prospective way, validated this idea that we can use circulating tumor DNA as a prognostic marker. For this particular study, it doesn't look like this particular assay distinguished the two arms in terms of the PFS benefit that we observed with pola-R-CHP. Tycel J. Phillips: Sure. Alex F. Herrera: But I think it serves as a really good foundation to think about how we can design ctDNA-guided trials, right? Tycel J. Phillips: Okay. Alex F. Herrera: It kind of was the proof of concept. "Okay, we looked at earlier time points previously when we presented it at ASH, a certain log drop, certainly separated the curves. Now ctDNA clearance at the end of treatment separates curves. So, can we build on that to modify therapy? Can we intervene on patients who have a suboptimal response? Can we deescalate therapy in patients who have good responses?" So, I think it helps kind of build the foundation for ctDNA-guided research in the future. Tycel J. Phillips: Which, I think we all hope is the key moving forward so we can move beyond PET scans. Alex F. Herrera: Right, right. Yeah, I mean, PET scans... I mean, look, they were certainly an advance compared to what we were doing with CT scans- Tycel J. Phillips: Very much so. Alex F. Herrera: But they're imperfect, right? Tycel J. Phillips: Yes. Alex F. Herrera: And so maybe even we arrive at some combination of PET and ctDNA, there are different ways to approach it. But I think we are all hopeful that we will sharpen our tools, including even the ctDNA assays, to get at an assay that can really help us, both with prognostic information, but also to guide therapy. Tycel J. Phillips: I mean, I think this is all really exciting information and can't wait to see what the research moves and brings us in the future. So, thank you again for taking time to speak with us this afternoon. Alex F. Herrera: My pleasure. Tycel J. Phillips: All right. Alex F. Herrera: Thank you.

Related Videos

Lymphoma

Catherine C. Coombs, MD, on B-Cell Malignancies and Long-Term Safety of Pirtobrutinib

Catherine C. Coombs, MD, of the University of California, Irvine, discusses prolonged pirtobrutinib therapy, which continues to demonstrate a safety profile amenable to long-term administration at the recommended dose without evidence of new or worsening toxicity signals. The safety and tolerability observed in patients on therapy for 12 months or more were similar to previously published safety analyses of all patients enrolled, regardless of follow-up (Abstract 7513).

Lymphoma

Tycel J. Phillips, MD, and Alex F. Herrera, MD, on Classical Hodgkin Lymphoma: New Data on Nivolumab, AVD, and Brentuximab Vedotin

Tycel J. Phillips, MD, and Alex F. Herrera, MD, both of the City of Hope National Medical Center, discuss results from the SWOG S1826 study, which showed that nivolumab and AVD (doxorubicin, vinblastine, and dacarbazine) improved progression-free survival vs brentuximab vedotin plus AVD in patients with advanced-stage classical Hodgkin lymphoma. Longer follow-up is needed to assess overall survival and patient-reported outcomes. This trial may be a key step toward harmonizing the pediatric and adult treatment of advanced-stage disease (LBA4).

Breast Cancer

Lisa A. Carey, MD, and Dennis J. Slamon, MD, PhD, on Early Breast Cancer: Findings From the NATALEE Trial on Ribociclib Plus Endocrine Therapy

Lisa A. Carey, MD, of the University of North Carolina at Chapel Hill, and Dennis J. Slamon, MD, PhD, of the University of California, Los Angeles, discuss phase III study findings on ribociclib plus endocrine therapy as adjuvant treatment in patients with hormone receptor–positive, HER2-negative early breast cancer. When added to standard-of-care endocrine therapy, ribociclib improved invasive disease–free survival with a well-tolerated safety profile (Abstract LBA500).

Bladder Cancer

Enrique Grande, MD, on Metastatic Urothelial Carcinoma: Updated Data From IMvigor130

Enrique Grande, MD, of The University of Texas MD Anderson Cancer Center, discusses new findings that show initial responses to induction therapy with atezolizumab plus platinum and gemcitabine did not seem to impact overall survival for patients with metastatic urothelial carcinoma. Cisplatin-treated patients appeared to derive a greater benefit with atezolizumab than did carboplatin-treated patients (Abstract 4503).

Gynecologic Cancers
Immunotherapy

Bobbie J. Rimel, MD, Isabelle L. Ray-Coquard, MD, PhD, on Cervical Squamous Carcinoma: Neoadjuvant Nivolumab Plus Ipilimumab

Bobbie J. Rimel, MD, of Cedars-Sinai Medical Center, and Isabelle L. Ray-Coquard, MD, PhD, of Centre Léon Bérard and the University Claude Bernard Lyon Est, discuss findings from the COLIBRI trial, which showed that, for patients with cervical squamous cell carcinoma, neoadjuvant nivolumab plus ipilimumab is safe and orchestrates de novo immune responses. The 82.5% complete response rate for primary tumors 6 months after standard chemoradiation therapy suggests favorable clinical outcomes (Abstract 5501). 

Advertisement

Advertisement




Advertisement